Javascript must be enabled to continue!
Quick preparation of ABO‐incompatible living donor liver transplantation for acute liver failure
View through CrossRef
AbstractAcute liver failure is life‐threatening and has to be treated by liver transplantation urgently. When deceased donors or ABO‐compatible living donors are not available, ABO‐incompatible (ABO‐I) living donor liver transplantation (LDLT) becomes the only choice. How to prepare ABO‐I LDLT urgently is an unsolved issue. A quick preparation regimen was designed, which was consisted of bortezomib (3.5 mg) injection to deplete plasma cells and plasma exchange to achieve isoagglutinin titer ≤ 1: 64 just prior to liver transplantation and followed by rituximab (375 mg/m2) on post‐operative day 1 to deplete B‐cells. Eight patients received this quick preparation regimen to undergo ABO‐I LDLT for acute liver failure from 2012 to 2019. They aged between 50 and 60 years. The median MELD score was 39 with a range from 35 to 48. It took 4.75 ± 1.58 days to prepare such an urgent ABO‐I LDLT. All the patients had successful liver transplantations, but one patient died of antibody‐mediated rejection at post‐operative month 6. The 3‐month, 6‐month, and 1‐year graft/patient survival were 100%, 87.5%, and 75%, respectively. In conclusion, this quick preparation regimen can reduce isoagglutinin titers quickly and make timely ABO‐I LDLT feasible for acute liver failure.
Title: Quick preparation of ABO‐incompatible living donor liver transplantation for acute liver failure
Description:
AbstractAcute liver failure is life‐threatening and has to be treated by liver transplantation urgently.
When deceased donors or ABO‐compatible living donors are not available, ABO‐incompatible (ABO‐I) living donor liver transplantation (LDLT) becomes the only choice.
How to prepare ABO‐I LDLT urgently is an unsolved issue.
A quick preparation regimen was designed, which was consisted of bortezomib (3.
5 mg) injection to deplete plasma cells and plasma exchange to achieve isoagglutinin titer ≤ 1: 64 just prior to liver transplantation and followed by rituximab (375 mg/m2) on post‐operative day 1 to deplete B‐cells.
Eight patients received this quick preparation regimen to undergo ABO‐I LDLT for acute liver failure from 2012 to 2019.
They aged between 50 and 60 years.
The median MELD score was 39 with a range from 35 to 48.
It took 4.
75 ± 1.
58 days to prepare such an urgent ABO‐I LDLT.
All the patients had successful liver transplantations, but one patient died of antibody‐mediated rejection at post‐operative month 6.
The 3‐month, 6‐month, and 1‐year graft/patient survival were 100%, 87.
5%, and 75%, respectively.
In conclusion, this quick preparation regimen can reduce isoagglutinin titers quickly and make timely ABO‐I LDLT feasible for acute liver failure.
Related Results
ABO Gene and Fecundity
ABO Gene and Fecundity
ABO B allele is the lowest frequency allele at ABO gene so possible causes of its rarity including that of de-selection of phenotypes of ABO B including lower fecundity is addresse...
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
Application of Complement Component 4d Immunohistochemistry to ABO-Compatible and ABO-Incompatible Liver Transplantation
Application of Complement Component 4d Immunohistochemistry to ABO-Compatible and ABO-Incompatible Liver Transplantation
Antibody-mediated rejection (AMR) is difficult to diagnose after ABO-compatible or ABO-identical (ABO-C) liver transplantation. To determine whether complement component 4d (C4d) i...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Impact of ABO Blood Group Incompatibility on Outcomes after Single-Unit Umbilical Cord Blood Transplantation for Malignant Hematological Disease
Impact of ABO Blood Group Incompatibility on Outcomes after Single-Unit Umbilical Cord Blood Transplantation for Malignant Hematological Disease
Objective
In contrast to solid organ transplantation, ABO blood group incompatibility was acceptable in allogeneic hematopoietic stem cell transplantation (allo-HSCT...
ABO-incompatible kidney transplantation
ABO-incompatible kidney transplantation
Purpose of review
A dramatic shortage of available organs around the world encouraged attempts to cross previously forbidden immunological boundaries in kidney transpla...
Present status of ABO‐incompatible kidney transplantation in Japan
Present status of ABO‐incompatible kidney transplantation in Japan
Abstract: Background: We have been making continuous efforts in ABO‐incompatible kidney transplantation since 1989 to expand the opportunities for kidney transplantation from livi...

